Robert Kremer - Trulieve Cannabis Exec Communications
TCNNF Stock | USD 6.31 0.08 1.28% |
Insider
Robert Kremer is Exec Communications of Trulieve Cannabis Corp
Phone | 850 480 7955 |
Web | https://www.trulieve.com |
Trulieve Cannabis Management Efficiency
The company has return on total asset (ROA) of 0.0479 % which means that it generated a profit of $0.0479 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1421) %, meaning that it generated substantial loss on money invested by shareholders. Trulieve Cannabis' management efficiency ratios could be used to measure how well Trulieve Cannabis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Dominic Cundari | DiaMedica Therapeutics | 73 | |
MD MBA | Rezolute | N/A | |
, MBA | Molecular Partners AG | 51 | |
Andreas EMBA | Molecular Partners AG | 58 | |
Daniel Ryweck | Silo Pharma | 59 | |
Christopher Roenfeldt | Forte Biosciences | N/A | |
Thomas Schwerzmann | Molecular Partners AG | N/A | |
RAC Sakai | Tempest Therapeutics | N/A | |
Seth Lewis | Molecular Partners AG | N/A | |
Steven Ruhl | Forte Biosciences | 67 | |
Michael Pitzner | Molecular Partners AG | N/A | |
Robyn Sweinhart | Rezolute | N/A | |
Joseph Hazelton | Dyadic International | 48 | |
Patrick Amstutz | Molecular Partners AG | 49 | |
Justin Trojanowski | Tempest Therapeutics | 36 | |
Brian MD | Rezolute | 49 | |
Antony CPA | Forte Biosciences | 57 | |
Dr Dubensky | Tempest Therapeutics | 66 | |
Edward Calamai | DiaMedica Therapeutics | N/A | |
LLM JD | Rezolute | 63 | |
Petpiboon Prasit | Tempest Therapeutics | N/A |
Management Performance
Return On Equity | -0.14 | |||
Return On Asset | 0.0479 |
Trulieve Cannabis Corp Leadership Team
Elected by the shareholders, the Trulieve Cannabis' board of directors comprises two types of representatives: Trulieve Cannabis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Trulieve. The board's role is to monitor Trulieve Cannabis' management team and ensure that shareholders' interests are well served. Trulieve Cannabis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Trulieve Cannabis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kimberly Rivers, Chairman Founder | ||
Rebecca Young, VP Officer | ||
Alex CPA, Chief Officer | ||
Robert Kremer, Exec Communications | ||
JD III, Chief Sec | ||
Jason Pernell, Chief Officer | ||
Victoria Walker, Director Relations | ||
Nilyum Jhala, Chief Officer | ||
Christine Hersey, Director Relations | ||
Steven White, President |
Trulieve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Trulieve Cannabis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.14 | |||
Return On Asset | 0.0479 | |||
Profit Margin | (0.19) % | |||
Operating Margin | 0.14 % | |||
Current Valuation | 2.48 B | |||
Shares Outstanding | 159.64 M | |||
Shares Owned By Insiders | 8.76 % | |||
Shares Owned By Institutions | 12.51 % | |||
Price To Earning | 23.96 X | |||
Price To Book | 0.83 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Trulieve OTC Stock
Trulieve Cannabis financial ratios help investors to determine whether Trulieve OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Trulieve with respect to the benefits of owning Trulieve Cannabis security.